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ABSTRACT
Induced pluripotent stem cells (iPSCs) are new diagnostic and potentially therapeutic tools
to model disease and assess the toxicity of pharmaceutical medications. A common limita-
tion of cell lineages derived from iPSCs is a blunted phenotype compared with fully devel-
oped, endogenous cells.Weexamined the influence of novel three-dimensional bioartificial
microenvironments on functionandmaturationof hepatocyte-like cells differentiated from
iPSCs andgrownwithin anacellular, liver-derivedextracellularmatrix (ECM) scaffold. Inpar-
allel, we also compared a bioplotted poly-L-lactic acid (PLLA) scaffold that allows for cell
growth in three dimensions and formation of cell-cell contacts but is infusedwith type I col-
lagen (PLLA-collagen scaffold) alone as a “deconstructed” control scaffold with narrowed
biological diversity. iPSC-derived hepatocytes cultured within both scaffolds remained via-
ble, became polarized, and formed bile canaliculi-like structures; however, cells grown
within ECM scaffolds had significantly higher P450 (CYP2C9, CYP3A4, CYP1A2) mRNA levels
andmetabolic enzyme activity comparedwith iPSC hepatocytes grown in either bioplotted
PLLA collagen or Matrigel sandwich control culture. Additionally, the rate of albumin syn-
thesis approached the level of primary cryopreserved hepatocyteswith lower transcription
of fetal-specific genes,a-fetoprotein andCYP3A7, comparedwith eitherPLLA-collagen scaf-
folds or sandwich culture. These studies show that two acellular, three-dimensional culture
systems increase the function of iPSC-derived hepatocytes. However, scaffolds derived
from ECM alone induced further hepatocyte maturation compared with bioplotted PLLA-
collagen scaffolds. This effect is likely mediated by the complex composition of ECM scaf-
folds in contrast tobioplotted scaffolds, suggesting theirutility for in vitrohepatocyteassays
or drug discovery. STEM CELLS TRANSLATIONALMEDICINE 2016;5:1257–1267
SIGNIFICANCE
Through the use of novel technology to develop three-dimensional (3D) scaffolds, the pre-
sent study demonstrated that hepatocyte-like cells derived via induced pluripotent stem
cell (iPSC) technology mature on 3D extracellular matrix scaffolds as a result of 3D matrix
structure and scaffold biology. The result is an improved hepatic phenotypewith increased
synthetic andcatalytic potency, an improvementon thebluntedphenotypeof iPSC-derived
hepatocytes, a critical limitation of iPSC technology. These findings provide insight into the
influence of 3D microenvironments on the viability, proliferation, and function of iPSC he-
patocytes to yield a more mature population of cells for cell toxicity studies and disease
modeling.
INTRODUCTION
Induced pluripotent stem cell (iPSC) technol-
ogy is a powerful strategy to developmultipo-
tent cells frommature tissues with the ability
to direct differentiation toward any tissue
lineage to model disease [1–6], analyze drug
pharmacokinetics [7], andpotentially develop
cells as therapies for a variety of diseases
[8–11]. The development of patient-specific
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hepatocyteswith intact synthetic xenobiotic catalytic activitywould
accelerate pharmaceutical testing and drug development. How-
ever, the ability of iPSC-derived hepatocytes to replicate the func-
tion of endogenous cells is limited by a blunted phenotype with
reduced synthetic ability and metabolic enzyme activity.
Primary hepatocytes are in high demand as a cell source for
pharmacology and toxicity testing owing to their synthetic and de-
toxificationactivitiesandbecausetoxicity isacommonfailuremode
in thedevelopmentof newdrugs.However, theuseof primary cells
has been limited by low proliferative capacity, loss of function in
vitro, and tendency for dedifferentiation during prolonged culture
[12]. Several strategies todevelophepatocyte-like cells fromplurip-
otent stem cells (iPSCs and embryonic stem cells) have been estab-
lished because of this important role in pharmaceutical testing and
discovery [13–19]. The resulting hepatocyte-like cells express he-
patic lineage markers (e.g., cytokeratin-7, 8, and 18, albumin,
CYP7A1, hepatocyte nuclear factor-4a) and secrete liver-specific
proteins (e.g., albumin,a1-antitrypsin).However, they consistently
retainamixed immaturephenotypewithexpressionofa-fetoprotein
(AFP) and decreased overall cellular potency relative to primary
hepatocytes, leading to the slowermetabolismof toxins and small
molecules by the cytochrome P450 system [17, 19–21]. Few syn-
thetic three-dimensional (3D) cell culture systems, such as rudimen-
tary collagenmatrices [22] or spheroid culture [23], recreate cell-cell
junctions and, thus, liver architecture, more effectively than tradi-
tional sandwich cultures and lead to enhanced iPSC hepatocyte
function. Compared with these defined culture environments,
the natural liver extracellular matrix (ECM) is biochemically com-
plex, containing more active substrates with a diverse repertoire
ofproteinswithbiological function, carbohydrates,andgrowth fac-
tors. Thenatural liverECMhasrecentlybeenshowntomaintain the
phenotype of primary rat hepatocytes for a short duration in vitro
[24]. In the present study, we investigated whether ECM might
mimic the in vivo liver architecture to enhance proliferation, func-
tion, and maturation of iPSC hepatocytes during in vitro culture.
Biomimetic coculture of human iPSC hepatocytes with rodent-
derived, facilitatingstromacells leadstoamorerobusthepaticphe-
notype, as others have shown. However, the addition of a xenoge-
neic cell population limits the potential therapeutic application of
the iPSC-derived population [21]. The objectives of our study were
to develop a cell-free scaffold system that would enhance function
of cultured iPSC hepatocytes and todetermine the differential con-
tribution of naturally occurring ECM-derived scaffolds compared
with a biosynthetic 3D-printed scaffold. We developed a structur-
ally complex 3D scaffold derived fromadecellularized rat liver ECM
(ECM scaffold) using perfusion decellularization [25–28], which re-
tains the chemical compositionof the livermatrixbut is small in size
(∼8mm), allowing for rapid characterization of evolving cell pheno-
typesovermultipleweeks. Tocontrol for the influenceof the raw3D
structure on cell-cell interactions compared with the “outside-in”
signaling capacity of the matrix niche of the ECM scaffold, we also
used 3D bioplotting technology to print hybrid scaffolds composed
of poly-L-lactic acid (PLLA) coated and infused with type I collagen
only (PLLA-collagen scaffold) to represent a “deconstructed” 3D
scaffold with structural homogeneity but limited chemical intricacy
compared with the ECM scaffold. Both systems were further com-
pared with the widely used reference standard control of hepato-
cyte sandwich culture. We found that prolonged culture within
the ECM scaffolds enhancedmaturation and function of iPSC hepa-
tocytes compared with the growth in the PLLA-collagen scaffolds,
although both environments allow for 3D growth and development
of cell-cell contacts, together suggesting that discrete cell-matrix in-
teractions are important for cellular maturation.
MATERIALS AND METHODS
Development of ECM and Bioplotted Scaffolds
ECM Scaffolds
Male Sprague-Dawley rats weighing 220–250 g (Charles River Lab-
oratories, Wilmington, MA, http://www.criver.com) were cared
for in accordance with protocols approved by the institutional an-
imal care anduse committee of NorthwesternUniversity. After ad-
equate induction of anesthesia, 2 3 103 U/kg body weight of
heparin was injected intravenously. The liver was isolated and per-
fused with 20 ml of cold saline and decellularized by the perfusion
of agents through a portal vein cannula: deionizedwater, followed
by the decellularization solution (1% Triton X-100 and 0.1%
NH4OH), and rinsed with deionized water [26]. To prepare the
ECM scaffolds, decellularized liver lobes were embedded within
optical cutting temperature compound, flash frozen, sectioned
to a thickness of 500 mm, and biopsy punched into 8-mm-
diameter disks (Integra Miltex, York, PA, http://www.miltex.com).
PLLA-Collagen Scaffolds
A 3D bioplotter (EnvisionTEC GmbH, Gladbeck, Germany, http://
www.envisiontec.com) was used to fabricate PLLA-collagen
scaffolds (8-mmdiameter, 500-mmthick). PLLA (Corbion,Amsterdam,
The Netherlands, http://www.corbion.com) was melted at 220°C,
3D-printedvia hot-melt extrusion onto a stage heated to60°C, sub-
sequentlytreatedwith70%ethanol toreduce inherenthydrophobicity
and induce surface hydrophilicity, and infused with 0.05 wt%
type I bovine collagen solution in 50 mM acetic acid. The infused
scaffolds were immediately frozen at280°C for several hours be-
fore lyophilization.
Cells and Culture Conditions
Individual scaffolds were placed in a 48-well cell culture plate
(Thermo Fisher Scientific Life Sciences, Waltham, MA, http://www.
thermofisher.com), sterilized with 70% ethanol, and incubated at
37°C overnight in hepatocytemedium (Roswell ParkMemorial In-
stitute 1640medium; Thermo Fisher Scientific Life Sciences) with
B27 (Thermo Fisher Scientific Life Sciences), 20 ng/ml oncostatin
M (R&D Systems, Minneapolis, MN, http://www.rndsystems.
com), 0.1 mM dexamethasone (Thermo Fisher Scientific Life Sci-
ences), and25mg/mlgentamicin (ThermoFisherScientific LifeSci-
ences). The scaffoldswere dried for 5minutes before cell seeding.
Human iPSC hepatocytes (iCell Hepatocytes; Cellular Dy-
namics International, Madison, WI, http://www.cellulardynamics.
com) were received fresh, in suspension, within a T-flask at room
temperature. All cells were differentiated from a single-donor
iPSC clone. The results frommultiple production (differentiation)
runs were found to yield consistent results. The cells were grown
and handled according to the manufacturer’s recommendations.
A20-ml cell suspension containing 13106 cellswas pipettedonto
each scaffold, and the cellswere allowed to attach for 20minutes.
Next, 10 of each scaffold typewith cells were transferred to a T25
flask, and 10mlof hepatocytemedium (InVitro Technologies Inc.,
Baltimore, MD, http://www.invitrotech.com) was added. The
scaffolds were maintained under dynamic culture conditions at
37°C and 5% CO2 on an orbital shaker (Stovall Life Science,
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Greensboro, NC, http://www.ibisci.com) set at 1 rotation per sec-
ond to prevent settling of the scaffolds on the bottom of the flask
and minimizing foam formation on the surface of the media.
In the sandwich control group, 0.5 3 106 iPSC hepatocytes
were seeded onto 24-well polystyrene plates coated with a
type 1 collagen gel (BD Biosciences, San Jose, CA, http://
www.bdbiosciences.com). Next, 0.5 ml of hepatocyte medium
was added tomaintain the same cell/media ratio used inmicroscaf-
foldcultureconditions. The followingday,0.25mg/mlgrowth factor-
reducedMatrigel Matrix (BD Biosciences) was placed over the cells.
Fresh primary human hepatocytes expanded in triple knockout
Fah2/2/Rag22/2/Il2rg2/2 mice (Yecuris Inc., Tualatin, OR, http://
www.yecuris.com) or cryopreserved primary human hepatocytes
(male, age56years; InVitroTechnologies Inc.)wereadoptedaspos-
itive controls. Primary hepatocytes in hepatocyte medium were
seeded onto the ECM, PLLA-collagen scaffolds, or type 1 collagen-
coated polystyrene plates with growth factor-reduced Matrigel
overlay using the samemethod described for the iPSC hepatocytes.
The cell culturemediumwaschangedeveryotherday for all groups.
DNA Quantification and Quantitative Reverse
Transcription-Polymerase Chain Reaction
TheamountofDNA remaining after cell removalwasused toeval-
uate the degreeof decellularization in the acellular scaffolds com-
pared with the normal (untreated) organ. The tissue was
completely dehydrated and DNA extracted and subsequently pu-
rified using a standard kit (Qiagen, Gaithersburg, MD, http://
www.qiagen.com). The DNA concentration was measured on a
nanodropmachine at 260 nmandwas represented as nanograms
of DNA per milligram of dry weight of the sample.
To quantify the cell proliferationwithin the scaffolds after 1, 3, 7,
and 14 days in culture, cell-laden scaffolds were digested using 0.1%
TritonX-100 for 30minutes, followedby 1minuteof ultrasonic treat-
ment (50 Hz; Branson Ultrasonics Corp., Danbury, CT, http://www.
emersonindustrial.com). DNA within the resulting lysates was mea-
suredbyreadingfluoresceinat485/535nmusingQuant-iTPicoGreen
kit (Thermo Fisher Scientific Life Sciences). Known concentrations of
iPSC hepatocytes and primary hepatocytes were used to construct a
standard curve and correlate the DNA concentration to cell number.
Atwo-stepquantitative real-timereverse transcriptionpolymer-
ase chain reactionwas performed at day 14. Total RNAwas isolated
using the TRI Reagent solution (Thermo Fisher Scientific Life Sci-
ences). Reverse transcription using the High Capacity RNA-to-
cDNA Kit (Thermo Fisher Scientific Life Sciences) was performed.
The mRNA expression of each target gene was normalized to cyclo-
philin expression. Primer sequences are shown in the supplemental
online data. Quantitative polymerase chain reactionwas performed
with iQ SYBRGreen and detected using the iQ5Optical System (Bio-
Rad Laboratories Inc., Des Plaines, IL, http://www.bio-rad.com). The
thermal profile usedwas 50°C for 2minutes, 95°C for 10minutes, 40
amplification cycles of 95°C for 60 seconds, and 58°C for 60 seconds.
The relative degree of gene amplification was calculated using
2^(Ct gene 2 – Ct Cyclophilin2) 2 (Ct gene 1 – Ct Cyclophilin 1). “Ct gene 1” rep-
resents the threshold cycle (Ct) of the target gene of the reference
population and “Ct gene 2” the target gene in the sample of interest.
ImmunohistochemicalCharacterization,ScanningElectron
Microscopy, and Transmission Electron Microscopy
The ECM specimens were fixed in 4% paraformaldehyde and stained
with hematoxylin and eosin (H&E). For immunohistochemistry
staining, after rehydration and antigen retrieval, the sections
were incubatedat4°Covernightwithanti-lamininB2-g1antibody
(1:100; Abcam, Cambridge,MA, http://www.abcam.com) or anti-
fibronectin antibody (1:100; Santa Cruz Biotechnology, Santa
Cruz, CA, http://www.scbt.com). The secondary antibody (goat
anti-mouse IgG horseradish peroxidase, 1:500; Abcam) was in-
cubated at room temperature for 60 minutes. Visualization
of the immunohistochemical reaction was performed with
3,39-diaminobenzidine/H2O2 solution (Nichirei Bioscience, Tokyo,
Japan, http://www.nichirei.co.jp) and counterstained with Mayer’s
hematoxylin. H&E and immunohistochemical characterization could
not beperformedonPLLA-collagen specimensowing to the sensitiv-
ity to histological solvents and the resulting inability of the sample to
remain fixed to glass slides during the dehydration processes.
To assess cell viability, both ECM and PLLA-collagen scaffolds
were subjected to live-dead staining using a live/dead kit (Thermo
Fisher Scientific Life Sciences) and observed with the Nikon C2
confocal laser scanning system (Nikon Instruments, Tokyo, Japan,
http://www.nikoninstruments.com). For scanning electron mi-
croscopy (SEM), the samples were fixed in 5 wt% glutaraldehyde
for 4 hours, dehydrated in a graded ethanol series, critically point
dried, coated with osmium, and observed by SEM (LEO Gemini
1525; Leo Electron Microscopy, Inc., Cambridge, U.K., http://
www.smt.zeiss.com). For transmission electron microscopy
(TEM), the specimens were fixedwith 2.5% glutaraldehyde, subse-
quently postfixed with 1% osmium tetroxide for 1 hour, with 1%
uranyl acetate in maleate buffer for 1 hour, dehydrated with grad-
uated concentrations of ethanol and propylene oxide, and then
embedded in Epon (polymerized at 60°C for 48 hours). Ultrathin
specimens were observed using the Hitachi HT-7700 Biological
TEM (Hitachi, Tokyo, Japan, http://www.hitachi.com).
Measurement of CYP1A1, CYP2C9, and CYP3A4
Enzyme Activities
Cells seeded in sandwich control culture, ECM, and PLLA-collagen
scaffolds treatedwith orwithout induction agents (5mM3-meth-
ylcholanthrene for CYP1A2 or 50 mM rifampicin for CYP2C9 and
CYP3A4) for 48 hours were incubated with 100 mM Luc-ME
(CYP1A2) for 0.5 hour, 100 mM Luc-H (CYP2C9) for 4 hours, or
3 mM Luc-IPA (CYP3A4) for 0.5 hour (Promega, Madison WI,
http://www.promega.com). Next, 100ml of this luciferinmedium
was added to a 96-wellwhite opaqueplatewith 100ml of luciferin
detection reagent, and the luminescence signal wasmeasured on
a Cytation 3 Cell Imaging Multi-Mode Reader (BioTek Inc.,
Winooski, VT, http://www.biotek.com). After determining theac-
tivity, the amount of cells in each scaffold or sandwich culturewas
analyzed using the Quant-iT PicoGreen Kit (Thermo Fisher Scien-
tific Life Sciences) and the described protocols.
Statistical Analysis
Experimental data are presented as the mean 6 SD. One-way
analysis of variance was used for statistical analysis, with the
Holm-Sidak test used for post hoc pairwise comparisons and test-
ing against the control group. The Student t test was applied for
two-group comparisons using SPSS (IBM Corp., Armonk, NY,
http://ibm.com) and Microsoft Excel software (Microsoft Corp.,
Redmond, WA, http://www.microsoft.com). Differences were
considered statistically significant atp # .05.Additionalmethods
are available in the supplemental online data.
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RESULTS
Development and Characterization of 3D Liver
ECM Bioscaffolds
Acellular ECM scaffolds were developed by sequential perfusion
of weak detergents through the liver vasculature (supplemental
online Fig. 1A). The resulting scaffold appeared opaque
(supplemental online Fig. 1A), and quantitative DNA analysis
revealed a 98.9% reduction in DNA content after decellularization
(native liver, 6163.7 6 1221.6 ng/mg; decellularized ECM, 67.9 6
7.7 ng/mg; p , .01; n = 4 for each group). Despite the near ab-
sence of DNA, indicating removal of the cellular compartment,
the growth factors remained immobilized to structural proteins
of the ECM. The content of hepatocyte growth factor (HGF)
was 41.61 6 13.36 ng/g in the decellularized liver matrix and
86.89 6 16.76 ng/g in the native, untreated liver (p , .01). The
content of basic fibroblast growth factor (bFGF) was 21.80 6
5.02 ng/g in the decellularized liver scaffold and 45.50 6 12.36
ng/g in the native, untreated liver (p = .03; supplemental online
Fig. 1B). These results indicate that ∼50% of HGF and bFGF were
preserved after decellularization, similar to scaffolds developed
using other cell-removal strategies [25]. Fibronectin, laminin,
and type I collagen proteins were further detected in the liver
ECM by Western blot (supplemental online Fig. 1C). SEM and he-
matoxylin and eosin staining of the decellularized livermatrix also
revealed the acellularity of liver ECM with preservation of the 3D
lacunae structure (supplemental online Fig. 1D). Immunohisto-
chemical characterization of the liver ECM (supplemental online
Fig. 1D) further confirmed the matrix content and found laminin
and fibronectin to bemore prevalent around the vessel remnants
and Glisson’s capsule.
Individual ECM scaffolds (Fig. 1A, left), measuring 8mm in di-
ameter, were developed from the decellularized liver matrix, and
preservation of the ECM porous microstructure was revealed by
H&E staining (Fig. 1B) and SEM imaging (Fig. 1C). As a comparison
matrix, we also developed a bio-hybrid PLLA-collagen scaffold
(Fig. 1A, right) as a “deconstructed” 3D environment possessing
an open pore structure and containing only type 1 collagen with-
out growth factors (supplemental online Fig. 1B) or other struc-
tural proteins (supplemental online Fig. 1C). These scaffolds are
composedof four 125-mm-thick layers (Fig. 1D). Each layer is com-
posed of parallel PLLA struts measuring 150 mm in width and
spaced 200 mm apart, with each successive layer oriented 30°
with respect to the previous layer to mimic the porous nature
of the liver ECM, albeit with a more homogenous architecture
and thicker strut size afforded by the 3D bioprinting process
(Fig. 1E). Infused collagen fiberswere observed between the PLLA
struts by SEM (Fig. 1F).
Cell Viability, Proliferation, and Migration
We performed initial phenotyping of commercially available, dif-
ferentiated iPSC hepatocytes to establish a baseline and assess
the initial hepatocyte-like characteristics compared with fresh
primary hepatocytes. We found that hepatocyte-like cells differ-
entiated from iPSCs express genes signifying hepatocyte lineage
differentiation, albeit at a lower level (supplemental online
Fig. 2A) with poorer synthetic function (albumin production;
supplemental online Fig. 2B) and lower P450 enzyme activity
(supplemental online Fig. 2C) compared with fresh primary hu-
manhepatocytes. The fetal hepatocytemarkers, AFP andCYP3A7,
were increased in iPSC hepatocytes compared with fresh primary
hepatocytes. To assess the ability of our cell-free scaffolds to in-
fluence iPSC hepatocyte function and maturation, cells were
seeded onto ECM or PLLA-collagen scaffolds or grown between
a type 1 collagen monolayer and Matrigel overlay in a standard-
ized control sandwich culture. SEM imaging of cell-laden scaffolds
showed abundant iPSC hepatocytes within the interconnecting
pore structure of the collagen network in the PLLA-collagen scaf-
folds and within the ECM scaffolds for 2 weeks (Fig. 2). Live/dead
staining of iPSChepatocyteswithin the scaffolds revealed that the
cells remained viable and evenly distributed across the scaffolds
after 14 days of culture (Fig. 2). H&E staining of ECM scaffolds in
Figure 1. Matrix architecture of three-dimensional extracellular matrix (ECM) and bioplotted poly-L-lactic acid (PLLA)-collagen scaffolds. (A):
ECM scaffold (left) and porous PLLA-collagen scaffold (right). (B, C): Surface view of the ECM scaffold by hematoxylin and eosin staining (B) and
scanning electron microscopy (SEM) imaging (C). (D, E): Computer-aided schematic diagram of the PLLA-collagen scaffold showing struts and
pores. (F): SEMmicrograph of the surface of PLLA-collagen scaffold depicting type 1 collagen infused between PLLA struts. Scale bars = 200mm.
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cross-section depicted cell attachment at day 1 and multilayered
cell attachment after day 3, with penetration and migration into
the matrix and formation of cell-cell connections on day 7, which
continued through day 14 (Fig. 3). Bile canaliculi-like structures
and formation of tight junctions between adjacent iPSC hepato-
cytes were observed on both ECM (Fig. 3; supplemental online
Fig. 3) and PLLA-collagen (supplemental online Fig. 3) scaffolds
by 7 days.
Total DNA contentwas used to determine the cell density and
proliferation of iPSC hepatocytes in ECM, PLLA-collagen scaffold,
and sandwich control groups at day 1, which was 0.276 0.113
106, 0.396 0.133 106, and 0.506 0.153 106 cells per scaffold,
respectively. The cell density in both engineered scaffolds in-
creased during the first 7 days, with a 1.7-fold increase in iPSC he-
patocytes grown in either the ECM scaffold or PLLA-collagen
scaffold. The cell density of the sandwich control group did not
show any significant change, indicating an absence of prolifera-
tion during the 14-day culture period (p = .54; Fig. 4A).
Increased Expression of Hepatocyte-Specific Markers in
ECM Scaffolds
mRNAtranscriptsencodingphase I and II xenobioticenzymes (CYP1A2,
CYP2C9, CYP3A4, and human 3-hydroxy-3-methylglutaryl-coenzyme
A reductase [HMGCR]) assessed on day 14 were higher in iPSC
hepatocytes grown in either ECM or PLLA-collagen scaffolds
compared with the sandwich control group. Expression of
CYP2C9 increased approximately threefold, CYP3A4 increased
approximately eightfold, and HMGCR, a rate-limiting enzyme
in the isoprenoid/cholesterol biosynthesis pathway and in-
volved in cholesterol metabolism [29], increased approxi-
mately sixfold (Fig. 4B) compared with the sandwich control
group. In addition, iPSC hepatocytes grown within ECM scaf-
folds had significantly highermRNA levels comparedwith those
in the less chemically intricate PLLA-collagen scaffolds: CYP1A2
(1.7-fold; p = .039), CYP2C9 (1.7-fold; p = .028), and HMGCR
(3.3-fold; p = .02). However, mRNA synthesis of amitochondrial
membrane respiratory chain enzyme (NDUFA3; Fig. 4C; p = .11,
Figure 2. Induced pluripotent stem cell (iPSC) hepatocytes survive and grow within ECM and PLLA-collagen scaffolds. SEM micrographs of
recellularized ECM and PLLA-collagen scaffolds with iPSC hepatocytes over 14 days during an in vitro time course study. Red dashed lines de-
lineate boundaries between PLLA bioprinted struts and infused type 1 collagen within three-dimensional bioprinted PLLA-collagen scaffolds.
Staining of iPSC hepatocytes within ECM scaffolds or PLLA-collagen scaffolds showed live cells (green) with minimal dead cells (red) at day 14.
Scale bars = 50 mm. Abbreviations: ECM, extracellular matrix; PLLA, poly-L-lactic acid; SEM, scanning electron microscopy.
Figure 3. Inducedpluripotent stemcell (iPSC) hepatocytes develop cell-cell contacts andbiliary canaliculi within ECMscaffolds. Cross-sectional
view of the ECM scaffold without cells and recellularized ECM scaffolds with iPSC hepatocytes after 1, 3, 7, and 14 days of in vitro culture by
hematoxylin and eosin staining; scale bar = 50mm. iPSC hepatocytes penetrated into the scaffold over time, indicatingmigration into thematrix
scaffold. Insets: Highermagnification of iPSC hepatocytes within ECM scaffolds over time (363; scale bars = 20mm). TEMof iPSC hepatocytes in
the ECM scaffold depicts formation of bile canaliculi-like structures flanked by tight junctions at day 7 (bottom right panel, scale bars = 1 mm;
higher magnification shown in supplemental online Fig. 3). Abbreviations: BC, biliary canaliculi-like structures; ECM, extracellular matrix; LG,
lipid globule; M, mitochondria; TEM, transmission electron microscopy; TJ, tight junction.
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ECM vs. sandwich control), a glutathione synthesis enzyme (GSTA1;
Fig. 4C; p = .32, ECM vs. sandwich control), and albumin (Fig. 4C,
p = .11, ECM vs. sandwich control) did not show significant dif-
ferences between ECM scaffolds and either the PLLA-collagen
scaffolds or sandwich control group.
To investigate potential phenotypic maturation of cells in
ECM scaffolds, mRNA transcripts of fetal markers CYP3A7 and
AFP in iPSC hepatocytes grown in ECM scaffolds displayed a de-
creasing trend at day 14 (CYP3A7, 49% of sandwich control [p =
.16]; AFP, 47% of sandwich control [p = .041]). However, both
CYP3A7 and AFP remained essentially unchanged in the PLLA-
collagen scaffold (CYP3A7, 93% of sandwich control [p = .64];
AFP, 94% of sandwich control [p = .54]; Fig. 4D).
Synthesis of albumin by iPSC hepatocytes grown within the
ECM was significantly higher than that in the sandwich control
group throughout the 14-day culture period (p , .01; Fig. 5A)
and was similar to that in the PLLA-collagen scaffolds (p = .58).
Nonetheless, at day 14, albumin synthesis by iPSC hepatocytes
grown within ECM scaffolds (2.18 6 0.47 mg/day per 106 cells)
was slightly lower than at day 7 (Fig. 5A) but was not significantly
different from that of primary human hepatocytes grown within
the ECM scaffolds (2.75 6 0.31 mg/day per 106 cells; p = .057;
supplemental online Fig. 4) over the same time course.
AFP production in iPSC hepatocytes grown within ECM scaf-
folds consistently and significantly decreased from a baseline on
day 1 (21.216 1.27 mg/day per 106 cells) through day 7 (8.036
0.82mg/day per 106 cells; p, .01) to day 14 (5.986 1.78mg/day
per 106 cells; p, .01; Fig. 5B). However, AFP synthesis in iPSC he-
patocytes grown within the sandwich control environment did
not show any significant decline during this interval (p = .87).
Moreover, AFP production in PLLA-collagen scaffolds decreased
slightly until day 14 (19.86 6 1.39 mg/day per 106 cells on day
1; 14.196 0.69mg/day per 106 cells on day 14;p = .015), although
it did not reach the low level of synthesis found in iPSC hepato-
cytes grown in ECM scaffolds. This finding suggests that themore
complex biochemical milieuwithin the ECM scaffolds leads to the
enhancedmaturation of iPSC hepatocytes. Nonetheless, AFP syn-
thesis in primary human hepatocytes remained low compared
with that in iPSC hepatocytes grown in all environments (p ,
.01; supplemental online Fig. 4). Using the ratio of albumin to
AFP synthesis as a gauge of cellular maturation, iPSC hepatocytes
grown in ECM scaffolds consistently had a higher ratio compared
with cells grown in either PLLA-collagen scaffolds or sandwich cul-
ture (Fig. 5C), clearly demonstrating cellular maturation in the
ECM bioscaffold system.
Increased Liver-Specific Function in 3D ECM Scaffolds
Notably, CYP2C9 activity was nearly undetectable in iPSC hepato-
cytes before growth within scaffolds (supplemental online Fig.
2C) or within the sandwich control environment, ECM, or PLLA-
collagen scaffolds at day 3 (Fig. 6A). Nonetheless, on day 7, the
CYP2C9 activity of iPSC hepatocytes in ECM scaffolds increased
20.2-fold (Fig. 6A) beyond that of iPSC hepatocytes grown in
Figure 4. iPSC hepatocyte culture within three-dimensional scaffolds leads to increased proliferation and expression of mature liver-specific
markers. (A): Cell proliferation of iPSC hepatocytes in ECM scaffolds, PLLA-collagen scaffolds, and sandwich controls (n = 4 samples for each
group). Quantitative reverse transcription-polymerase chain reaction ofmetabolic and synthetic genes in iPSC hepatocytes that either changed
(B)or remained stable (C) in response to growth in ECMandPLLA-collagen scaffolds comparedwith growth in standard sandwich control culture
at day 14. Fresh, human hepatocytes are shown for comparison. (D): Expression of fetal genes CYP3A7 and AFP in iPSC hepatocytes in ECM
scaffolds or PLLA-collagen scaffolds compared with control sandwich culture at day 14 (p, p, .05; pp, p, .01; n = 4 for each group). Abbre-
viations: AFP, a-fetoprotein; ECM, extracellular matrix; HMGCR, human 3-hydroxy-3-methylglutaryl-coenzyme A reductase; iPSC, induced plu-
ripotent stem cell; PLLA, poly-L-lactic acid.
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sandwich culture on the same day and was also significantly
higher than that in iPSC hepatocytes in PLLA-collagen scaffolds
(p = .02 for both; Fig. 6A). CYP3A4 activity in iPSC hepatocytes
grown within ECM scaffolds at day 14 was 3.6-fold higher than
that in iPSC hepatocytes in the sandwich control group (p ,
.01) and 1.3-fold higher than that in iPSC hepatocytes in the
PLLA-collagen scaffold (p = .02). CYP1A2 activity of iPSC hepato-
cytes grown on ECM scaffolds at day 14 was 1.8-fold higher than
that of iPSC hepatocytes in the sandwich control group (p = .01)
and1.5-fold higher than that of iPSChepatocytes in PLLA-collagen
scaffolds (p = .04; Fig. 6A). Rifampicin induced CYP3A4 activity by
twofold in iPSC hepatocytes within ECM scaffolds, slightly more
than that in iPSC hepatocytes within either the sandwich control
or PLLA-collagen scaffold on day 14 (Fig. 6B). However, induction
of CYP1A2 (by 3-methylcholanthrene) or CYP2C9 (by rifampicin)
in iPSC hepatocytes was modest compared with that in primary
hepatocytes. Taken together, the activity of CYP1A2, CYP2C9,
and CYP3A4 in iPSC hepatocytes tended to increase in 3D culture,
with ECM scaffolds conferring the most robust phenotype and
primary hepatocytes generally losing activity in all three environ-
ments over 2 weeks (Fig. 7).
DISCUSSION
iPSCs can be engineered from patient tissue and then differenti-
ated along defined developmental pathways toward maturity.
Thus, iPSC-derived cells have the same genetic makeup as the
donor patient, making them an ideal cell source for disease mod-
eling, pharmacokinetics, and hepatotoxicity testing. We hypoth-
esized that the 3Dmicroenvironment could enhance the growth,
function, and maturation of iPSC hepatocytes without the need
for coculture with a stromal cell population. To evaluate this,
we compared two cell-free scaffold systems, the first using natu-
ral ECM scaffolds, developed from decellularized rat livers that
contain the original pore architecture and overall structure of
the whole organ matrix, and a second, biosynthetic hybrid
PLLA-collagen scaffold developed using 3D bioplotting technol-
ogy, an advanced rapid-prototyping technique to produce geo-
metrically tunable micron-scale scaffolds. This new technology
allows us to create a “deconstructed” 3D control environment
to investigate themechanism of action by defining the incremen-
tal contribution of both the 3D architecture and the additive ma-
trix function by infusing collagen into the bioplotted scaffold.
Moreover, the small scale of both scaffolds provides an easy
and rapid platform for studies analyzing hepatocyte development
and drug efficacy and toxicity.
We demonstrated that decellularized rat ECM is cell-free by
histologic and electron microscopy analysis with ∼1% residual
DNA remaining compared with the native liver, similar to other
published decellularization strategies for tissues and organs
[25, 30]. Immunohistochemical and growth factor content analy-
ses of the decellularized ECM further demonstrated preservation
Figure 5. iPSC hepatocytes express a higher degree ofmaturity and albumin synthesis within ECM scaffolds. Graphs show albumin production
(A), AFP biosynthesis (B), and albumin/AFP protein synthesis ratio (C) in iPSC hepatocytes within ECM scaffolds, PLLA-collagen scaffolds, and
sandwich controls throughout 14daysof culture (pp,p, .01;n=4 for each group). Abbreviations:AFP,a-fetoprotein; ECM,extracellularmatrix;
iPSC, induced pluripotent stem cell; PLLA, poly-L-lactic acid.
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of fibronectin and laminin and∼50%HGF and FGF.Moreover, the
ECM scaffolds allowed iPSC hepatocyte survival, proliferation,
and migration within this natural matrix.
One universal limitation of hepatocyte-like cells differenti-
ated from iPSCs is their decreased phenotypic maturity with
lower liver-specific enzyme function compared with that of pri-
mary human hepatocytes [31]. However, iPSC hepatocytes
grown within our ECM scaffolds exhibited increased P450 func-
tion. Not only was the expression of CYP1A2 (acetaminophen
metabolism), CYP2C9 (warfarin metabolism), CYP3A4 (metabo-
lism of ∼50% of medications by the P450 system), and HMGCR
transcripts higher in iPSC hepatocytes grown on ECM scaffolds,
but this also translated into consistently higher P450 enzyme ac-
tivity in iPSC hepatocytes on a day-by-day basis in ECM scaffolds
compared with both “deconstructed” 3D controls (e.g., PLLA-
collagen) and standard sandwich cultures. We found that iPSC
hepatocytes display extremely low, and at times undetectable,
CYP2C9 activity at initial (day 0) and early time points (∼3 days)
in all environments, and this continued throughout the 14-day
culture period in standard sandwich cultures. CYP2C9 metabo-
lizeswarfarin andphenytoin at varying rates basedon the genet-
ic polymorphism present within each individual. The cause of
low CYP2C9 activity observed within the starting iPSC hepato-
cyte population is unclear, although it might result from the
known genetic heterogeneity at the CYP2C9 locus conferring de-
creased activity or altered transcriptional regulation. Nonethe-
less, the use of ECM scaffolds led to a 20-fold increase beyond
baseline in CYP2C9 activity at day 7. Although it is challenging
to compare hepatocyte characteristics between studies using
microscaffolding techniques owing to differences in controls,
data analysis, and normalization methods, other microscaffold-
ing systems have been developed to culture stem cell-derived
hepatocytes; however, none showed as robust or as early in-
duction of CYP2C9 [21, 23]. However, other liver ECM-basedbio-
matrix scaffolds have been developed by delipidation using a
separate strategy (phospholipase A2, high salt wash, and nucle-
ase treatment) to obtain a scaffold that was .95% DNA free
with retention of matrix-bound growth factors [32]. In that
Figure 6. ECM scaffolds confer increased P450 activity to iPSC hepatocytes. (A): CYP2C9, CYP3A4, and CYP1A2 activity in iPSC hepatocytes
within ECM scaffolds, PLLA-collagen scaffolds, and sandwich control environments at 3, 7, and 14 days of culture. (B): Response of iPSC hepa-
tocytes to treatment with P450 inducers, rifampicin (CYP2C9 and CYP3A4) and 3-methylcholanthrene (CYP1A2), within ECM scaffolds, PLLA-
collagen scaffolds, and sandwich controls at day 14 (p, p, .05; pp, p, .01; n = 3 for each group at each time point). Abbreviations: ECM,
extracellular matrix; iPSC, induced pluripotent stem cell; ND, not detected; PLLA, poly-L-lactic acid.
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study, Wang et al. [32] demonstrated a 1.3-fold increase in
CYP3A4 activity in cryopreserved human hepatocytes grown
on these scaffolds compared with the same cells grown on type
1 collagen but did not assess CYP2C9 activity. In the present
study, our ECM scaffold was produced with a distinct strategy
(1% Triton X-100 and 0.1% NH4OH) that likewise produced a
cell-free environment with bound growth factors and structural
proteins. As a model to promote cellular maturation in iPSC-
derived cells, we tested our 3D environments to enhance the
proliferation and phenotypic properties of iPSC-derived hepato-
cytes, a relatively new cell type, and showed that growthon ECM
scaffolds leads to a population closer to primary human hepato-
cytes with decreased AFP synthesis, an increased albumin/AFP
ratio, and a trend toward lower expression of fetal-specific
markers, AFP and CYP3A7. Together with the increasing enzyme
functionof CYP2C9, CYP3A4, andCYP1A2, this trendprovides ev-
idence that growth within ECM scaffolds helps to overcome a
primary obstacle of iPSC hepatocytes by conferring increasing
maturity and potency to hepatocyte-like cells derived from
iPSCs, which could be used by others to better model disease
or analyze the metabolism of pharmaceutical compounds.
Our use of bioprinting nanotechnology further allowed us to
develop 3D comparison environments to evaluate cell pheno-
types within a multidimensional, but chemically simplified, envi-
ronment to indicate thepotentialmechanisms leading to changes
in cell function observed in ECM scaffolds. Although clearly
Figure 7. P450 activity showed a trend toward higher in iPSC hepatocytes over time. CYP2C9, CYP3A4, and CYP1A2 activity showed a trend in
primary cryopreserved hepatocytes (A) and iPSC hepatocytes (B) within ECM scaffolds, PLLA-collagen scaffolds, and sandwich control groups
after 3, 7, and 14 days of culture. CYP activity of primary hepatocytes decreased and CYP activity of iPSC hepatocytes increased over time, with
ECM scaffolds conferring the most robust phenotype for both cell types. Data are presented as mean6 SD (n = 3 for each group at each time
point). Squares indicate ECM scaffold; triangles, PLLA-collagen scaffold; diamonds, sandwich control. p, Significant difference between ECM
scaffolds versus PLLA-collagen scaffolds or sandwich control groups; pp, significant differencebetweenECMscaffolds versus both PLLA-collagen
scaffolds and sandwich control groups; †, significant difference between PLLA-collagen scaffolds and sandwich control groups. Abbreviations:
ECM, extracellular matrix; iPSC, induced pluripotent stem cell; PLLA, poly-L-lactic acid.
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distinct fromnatural liver architecture, 3Dbioprinting technology
can be used to develop uniform, tunable scaffolds to evaluate cell
growthwithin a definedmatrix composition.Wehave shown that
bioplottedPLLA-collagen scaffolds provide a3Denvironment that
permits iPSC hepatocyte proliferation with increased expression
and activity of liver-specific enzymes relative to standard sand-
wich culture. However, the levels of each of these indexes were
lower in 3D-printed scaffolds than in the cells grown in ECM-
derived scaffolds. As such, the results from experiments using
PLLA-collagen printed scaffolds suggest that growth in 3D scaf-
folds and the presence of type 1 collagen encourage hepatocyte
function, albeit to a limited degree. A reduction in fetal genes
CYP3A7 and AFP was not observed in iPSC hepatocytes grown
onPLLA-collagen scaffolds, indicating that bothmultidimensional
growth and appropriate matrix biochemical complexity (e.g., in
chemically diverse ECMscaffolds) is a requirement formaturation
of iPSC hepatocytes.
Our use of 3D-printed scaffolds allowed a degree of compar-
ison with other collagen scaffolding systems such as the Real Ar-
chitecture for 3D Tissues [33] system (TAP Biosystems, Royston,
U.K., http://www.tapbiosystems.com), which uses type 1 colla-
genas a substrate [22].Using this system,Gieseck et al. [22] found
albumin secretion to be nearly constant at ∼1.0 mg/day per 106
cells 10–20 days after iPSC differentiation to a common hepato-
cyte progenitor cell. In contrast, our study showed that PLLA-
collagen scaffolds led to an albumin synthesis rate of ∼3 mg/day
per 106 cells and ECM scaffolds to an albumin synthesis rate
of ∼3–4 mg/day per 106 cells between days 7 and 14.
Although iPSC hepatocytes in all our three culture systems
remained immature compared with fresh human primary hepa-
tocytes, we showed a specific effect of ECM composition on
the biochemical function of iPSC hepatocytes compared with
PLLA-collagen scaffolds. ECMscaffolds containmultiple structural
proteins, including laminin and fibronectin, and growth factors
that are likely contributory on a multifactorial level through in-
duction of hepatic nuclear factors and gene networks. Further
metabolic maturation of iPSC hepatocytes might be possible in
both systems through coculture with liver stroma cells, which
have been shown to increase the catalytic function of iPSC hepa-
tocytes in biomimetic liver systems [21]. Our findings also suggest
that proliferation, maturation, and hepatic function of iPSC hepa-
tocytes might be further enhanced by producing highly con-
trolled, fully porous, custom synthetic scaffolds through 3D
bioprinting with increased matrix function by “adding back” indi-
vidual specific ECM components to develop fully synthetic scaf-
folds that retain the individual, structural building blocks that
maximize cell maturation. ECM scaffolds contain FGF, HGF, lam-
inin, fibronectin, and other matrix components that are absent
from 3D bioplotted PLLA-collagen scaffolds but might influence
maturation of iPSC hepatocytes in our system, as a recent study
revealed that a fragment of the ECM protein vitronectin can
replace Matrigel to support differentiation of iPSCs into
hepatocyte-like cells [34]. The development of tunable inks for
3Dbioprinting [35, 36] topermit the incorporationof specific struc-
tural, growth factor, and mitogenic components can eventually
lead to the development of fully synthetic scaffolds that confer a
maturationadvantage to iPSChepatocytes similar to thatofnatural
ECMscaffolds.Ongoingworkentails altering the synthetic, bioplot-
ted scaffold to better emulate the mechanical and bioactive prop-
erties of native liver tissue to determine direct influence on iPSC
hepatocyte function.
CONCLUSION
In the present study, we compared the effect of two 3D bioscaf-
fold systems to reverse the primary limitation of iPSC hepato-
cytes. We found that the cellular phenotypic properties of
proliferation, function, andmaturation are influenced todiffering
degreeswithin (a)biologically heterogeneous, naturally occurring
ECM scaffolds derived from decellularized liver tissue and (b) bio-
synthetic, collagen-infused 3D-printed porous PLLA scaffolds.
iPSC hepatocyte proliferation and function were significantly en-
hancedwhen culturedwithin ECM scaffolds compared with stan-
dard sandwich culture controls. In addition, although culture
within the biosynthetic PLLA scaffold improved some important
aspects of iPSC hepatocyte proliferation and function, of the
two3D-cultured systems, only theECMscaffold enhancedpheno-
typic maturation of iPSC hepatocytes compared with the other
platforms, likely because of its biologically diverse makeup, in-
cludingboth its 3Dconfiguration andbiological components, such
as growth factors and structural proteins that regulate cell func-
tion and intracellular signaling via transmembrane receptors.
Taken together, the small size of both 3D scaffolds allows for
rapid, careful analysis of key growth conditions, allowingmatrices
such as these to be used as high-throughput platforms to influence
the development of iPSC hepatocytes to ultimately model disease
or evaluate hepatotoxicity to small molecular pharmaceutics.
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